Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT7RGTM)

• DTT Name: Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DTT Info
• Gene Name: CACNA1D

Molecule-Related Drug & Molecule List

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[1]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[2]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[3]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[4]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[5]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[6]
azidopine	DMD0LCA	Discovery agent	N.A.	Investigative	[7]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[6]
CV-4093	DM983QP	Discovery agent	N.A.	Investigative	[1]
MEBUDIPINE	DM0P59E	Discovery agent	N.A.	Investigative	[8]
N,N'-Di-acenaphthen-5-yl-guanidine	DM8TA0M	Discovery agent	N.A.	Investigative	[2]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[9]
[3H](+)-isradipine	DM7QE1J	Discovery agent	N.A.	Investigative	[10]

References

• [1] Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
• [2] Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
• [3] CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
• [4] Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
• [7] Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14.
• [8] Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
• [9] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [10] alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6.